Use of hnRNPL in preparation of glioma diagnosis, treatment and prognosis evaluation products
By detecting hnRNPL expression levels and using inhibitors targeting hnRNPL to prevent exon skipping of SH3BGRL, the unclear molecular mechanism by which hnRNPL regulates downstream target genes in gliomas has been resolved, enabling precision diagnosis and treatment of gliomas and providing new molecular targets and treatment options.
CN122104920APending Publication Date: 2026-05-29TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL
- Filing Date
- 2026-04-27
- Publication Date
- 2026-05-29
Smart Images
Figure CN122104920A_ABST
Abstract
The application discloses application of hnRNPL in preparation of glioma diagnosis, treatment and prognosis evaluation products, and belongs to the technical field of biological medicine. Through bioinformatics and clinical sample verification, it is confirmed that hnRNPL is significantly highly expressed in glioma tissues, and the expression level thereof is negatively correlated with the total survival period of patients, and hnRNPL has the function of promoting the occurrence and development of glioma. Mechanism research shows that hnRNPL can be used as a key alternative splicing factor, which promotes the skipping of the second exon of SH3BGRL by combining with the CA-rich sequence on the SH3BGRL pre-mRNA, thereby generating functional SH3BGRL protein, and driving the proliferation, migration and invasion of glioma cells. Based on this, hnRNPL can be used as a molecular marker for the diagnosis and prognosis evaluation of glioma, and an inhibitor targeting hnRNPL can effectively inhibit the malignant progression of glioma.
Need to check novelty before this filing date? Find Prior Art